| ID | 1086 |
| Name of the vaccine | Quinvaxem inj. |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | From 6 weeks |
| Description of the vaccine | DTwP-HepB-Hib vaccine. |
| Name of the manufacturer | Berna Biotech Korea Corp. |
| Name of the manufacturing country | Korea |
| Year of manufacture | 2006 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | Predefined protective antibody level was 100% tetanus. |
| Vaccine formulation | Homogeneous liquid |
| Dosage | Primary vaccination : 3 doses of 0.5 mL each and one booster dose of 0.5 mL at 15-18 months. |
| Mechanism of action | Immunostimulants |
| Route of administration | Intramuscular |
| Indications | Primary and booster immunisation against diphtheria, tetanus, pertussis, hepatitis B, and invasive illness caused by H. influenzae type b. |
| Export | Distributed by: GlaxoSmithKline Pharmaceuticals Limited, India |
| Approval | WHO pre-qualified |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria, tetanus, pertussis and hepatitis B recombinant. |
| Side effects of vaccine | Temporary swelling, tenderness and redness together with fever, feeding disorders, sleepiness, irritability. |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | 22889824 |
| Clinical trial number | NA |
| Reference | https://india-pharma.gsk.com/media/787410/quinvaxem-with-gsk-as-distributor.pdf |
| Other name | NA |
| Additional Links | https://www.who.int/immunization_standards/vaccine_quality/pq_283_dtphepbhib_1dose_cPAD_Crucell_Korea_PI.pdf
|